92113
document
Effects of formoterol , salmeterol or oxitropium bromide on airway responses to salbutamol in COPD . We examined whether a pretreatment with formoterol , oxitropium bromide , or salmeterol might modify the dose-response curves to inhaled salbutamol in patients with stable and partially reversible chronic obstructive pulmonary disease ( COPD ) . Sixteen outpatients with partially reversible , stable COPD received 24 microg formoterol , 50 microg salmeterol , 200 microg oxitropium bromide , or placebo on four non-consecutive days . Spirometric testing was performed immediately before inhalation of treatment and after 2 h. A dose-response curve to inhaled salbutamol was then constructed using doses of 100 , 100 , 200 microg and 400 microg -- that is , a total cumulative dose of 800 microg . Dose increments were given at 20 min intervals with measurements being made 15 min after each dose . Formoterol , salmeterol , or oxitropium bromide elicited a significant increase in forced expiratory volume in one second ( FEV1 ) compared with placebo ( mean differences ( L ) = placebo 0.05 ; formoterol 0.34 ; salmeterol 0.27 ; oxitropium bromide 0.23 ) . Dose-dependent increases in FEV1 were seen ( mean values ( L ) before salbutamol and after a cumulative dose of 100 , 200 , 400 , and 800 microg = placebo : 1.06 , 1.28 , 1.35 , 1.39 , 1.41 ; formoterol : 1.33 , 1.37 , 1.41 , 1.44 , 1.44 ; salmeterol : 1.30 , 1.33 , 1.36 , 1.39 , 1.42 ; oxitropium bromide : 1.27 , 1.34 , 1.37 , 1.41 , 1.40 ) . Statistical analysis revealed no significant differences in FEV1 and forced vital capacity ( FVC ) responses to salbutamol after therapy with formoterol , salmeterol , or oxitropium bromide compared with placebo . This study clearly shows that a pretreatment with a conventional dose of formoterol , salmeterol , or oxitropium bromide does not preclude the possibility of inducing a further bronchodilation with salbutamol in patients suffering from partially reversible chronic obstructive pulmonary disease .
92114
Intervention_Pharmacological
formoterol
92115
Intervention_Pharmacological
salmeterol
92116
Intervention_Pharmacological
oxitropium bromide
92117
Intervention_Pharmacological
salbutamol
92118
Intervention_Pharmacological
formoterol
92119
Intervention_Pharmacological
oxitropium bromide
92120
Intervention_Pharmacological
salmeterol
92121
Intervention_Pharmacological
salbutamol
92122
Intervention_Pharmacological
24 microg formoterol
92123
Intervention_Pharmacological
50 microg salmeterol
92124
Intervention_Pharmacological
200 microg oxitropium bromide
92125
Intervention_Control
placebo
92126
Intervention_Physical
Spirometric testing
92127
Intervention_Pharmacological
salbutamol
92128
Intervention_Pharmacological
constructed using doses of 100 , 100 , 200 microg and 400 microg -- that is , a total cumulative dose of 800 microg
92129
Intervention_Pharmacological
Formoterol
92130
Intervention_Pharmacological
salmeterol
92131
Intervention_Pharmacological
oxitropium bromide
92132
Intervention_Control
placebo
92133
Intervention_Control
placebo
92134
Intervention_Pharmacological
formoterol
92135
Intervention_Pharmacological
salmeterol
92136
Intervention_Pharmacological
oxitropium bromide
92137
Intervention_Control
placebo
92138
Intervention_Pharmacological
formoterol
92139
Intervention_Pharmacological
salmeterol
92140
Intervention_Pharmacological
oxitropium bromide
92141
Intervention_Pharmacological
formoterol
92142
Intervention_Pharmacological
salmeterol
92143
Intervention_Pharmacological
oxitropium bromide
92144
Intervention_Control
placebo
92145
Intervention_Pharmacological
formoterol
92146
Intervention_Pharmacological
salmeterol
92147
Intervention_Pharmacological
oxitropium bromide
92148
Intervention_Pharmacological
salbutamol
92149
Outcome_Physical
airway responses to salbutamol
92150
Outcome_Other
dose-response curves to inhaled salbutamol
92151
Outcome_Other
dose-response curve to inhaled salbutamol
92152
Outcome_Other
forced expiratory volume in one second ( FEV1 )
92153
Outcome_Physical
FEV1
92154
Outcome_Other
FEV1 and forced vital capacity ( FVC ) responses
92155
Outcome_Physical
bronchodilation
92156
Participant_Condition
COPD .
92157
Participant_Condition
patients with stable and partially reversible chronic obstructive pulmonary disease ( COPD ) .
92158
Participant_Condition
partially reversible
92159
Participant_Condition
stable COPD